Literature DB >> 17548452

Neuromyelitis optica with clinical and histopathological involvement of the brain.

G J D Hengstman1, P Wesseling, C W G M Frenken, P J H Jongen.   

Abstract

Diagnostic criteria for neuromyelitis optica (NMO) state that there should be no active disease outside the optic nerves and spinal cord. However, several cases have been described with symptomatic brain involvement. We describe an autopsy case of a patient with NMO and symptomatic involvement of the brain. The histopathology of the brain lesions is typical for NMO, with extensive macrophage infiltration, including perivascular accumulation of large numbers of eosinophils. This is the first case that clearly shows that in NMO, the histopathology of the brain lesions is identical to that of the lesions in the optic nerves and spinal cord.

Entities:  

Mesh:

Year:  2007        PMID: 17548452     DOI: 10.1177/1352458506070145

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  18 in total

1.  T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.

Authors:  Robert C Axtell; Brigit A de Jong; Katia Boniface; Laura F van der Voort; Roopa Bhat; Patrizia De Sarno; Rodrigo Naves; May Han; Franklin Zhong; Jim G Castellanos; Robert Mair; Athena Christakos; Ilan Kolkowitz; Liat Katz; Joep Killestein; Chris H Polman; René de Waal Malefyt; Lawrence Steinman; Chander Raman
Journal:  Nat Med       Date:  2010-03-28       Impact factor: 53.440

Review 2.  Interferon-β exacerbates Th17-mediated inflammatory disease.

Authors:  Robert C Axtell; Chander Raman; Lawrence Steinman
Journal:  Trends Immunol       Date:  2011-04-29       Impact factor: 16.687

Review 3.  Type I interferons: beneficial in Th1 and detrimental in Th17 autoimmunity.

Authors:  Robert C Axtell; Chander Raman; Lawrence Steinman
Journal:  Clin Rev Allergy Immunol       Date:  2013-04       Impact factor: 8.667

4.  Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica.

Authors:  Hua Zhang; A S Verkman
Journal:  J Clin Invest       Date:  2013-04-08       Impact factor: 14.808

Review 5.  Monoclonal Antibody-Based Treatments for Neuromyelitis Optica Spectrum Disorders: From Bench to Bedside.

Authors:  Wenli Zhu; Yaling Zhang; Zhen Wang; Ying Fu; Yaping Yan
Journal:  Neurosci Bull       Date:  2020-06-12       Impact factor: 5.203

6.  Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59.

Authors:  Hua Zhang; A S Verkman
Journal:  J Autoimmun       Date:  2014-03-31       Impact factor: 7.094

Review 7.  [Neuromyelitis optica].

Authors:  S Jarius; B Wildemann
Journal:  Nervenarzt       Date:  2007-12       Impact factor: 1.214

8.  White matter atrophy and cognitive dysfunctions in neuromyelitis optica.

Authors:  Frederic Blanc; Vincent Noblet; Barbara Jung; François Rousseau; Felix Renard; Bertrand Bourre; Nadine Longato; Nadjette Cremel; Laure Di Bitonto; Catherine Kleitz; Nicolas Collongues; Jack Foucher; Stephane Kremer; Jean-Paul Armspach; Jerome de Seze
Journal:  PLoS One       Date:  2012-04-03       Impact factor: 3.240

9.  C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica.

Authors:  Puay-Wah Phuan; Hua Zhang; Nithi Asavapanumas; Michael Leviten; Arnon Rosenthal; Lukmanee Tradtrantip; A S Verkman
Journal:  Acta Neuropathol       Date:  2013-05-16       Impact factor: 15.887

Review 10.  Neuromyelitis optica pathogenesis and aquaporin 4.

Authors:  David J Graber; Michael Levy; Douglas Kerr; William F Wade
Journal:  J Neuroinflammation       Date:  2008-05-29       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.